高龄非瓣膜性房颤的华法林治疗11例体会

Experiences of warfarin therapy for 11 senilepatients with non-valvular atrial fibrillation

目的：探讨华法林治疗高龄非瓣膜性房颤患者安全有效的抗凝强度。方法：对11例高龄非瓣膜房颇有抗凝适应证者予华法林治疗，将抗凝强度控制在INR为1．5～2．0，观察疗效和出血并发症。结果：观察期间11例患者无致命性出血．仅1例皮肤出血且未停药。7例患者反复发作的短暂性脑缺血发作和脑梗塞症状得到控制。3例有2种以上危险因素的患者未出现栓塞并发症．结论：低抗凝强度（INR1．5～2．0）抗凝对高龄非瓣膜性房颤患者安全有效。

Objective： To discuss the safety and effectiveness of the anticoagulant intensity of warfarin therapy for senile patients with non-valvular atrial fibrillation （AF）. Methods： The 11 senile patients with AF had been selected for the anticoagulant warfarin therapy. The anticoagulant intensity had been controlled between INR 1.5-2.0. The effectiveness of the treatment and the bleeding manifest was observed, Results： None of the 11 patients had the symptom of lethal hemorrhage; but one patient had the cutis bleeding and the medication wasn＇t terminated after this manifest occurred. The symptoms of 7 patients who had recurrent transient ischemic attack （TIA） and ischemic stroke, had been control during the treatment. There were no thromboembolic complications for the other 3 patients who had more than two risk factors. Conclusion： Warfarin therapy is safe and effective for the senile patients with non-valvular atrial fibrillation when controlling the anticoagulant intensity between INR 1. 5-2. 0.